N/A
Completed N=30
The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.
Source: ClinicalTrials.gov NCT06111508 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcomePrimary: Change in Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) — 20.3; 8.3 percentage points — p=0.001
Summary
The goal of this clinical trial is to compare the effect of a continuous glucose monitor (CGM) based titration algorithm to standard titration by self-monitoring blood glucose (SMBG) in participants with Type 2 Diabetes already using long acting insulin. The comparison aims to study the difference in glycemic control between the two therapies. Participants will be followed for 18 weeks and will be provided with Degludec insulin, insulin pen, and a CGM (Dexcom G6).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) |
20.3; 8.3 | 0.001 sig |
| SECONDARY Change in HbA1c |
-0.74; -0.28 | — |
| SECONDARY Change in Time in Tight Range 3.9-7.8 mmol/L (70-140 mg/dL) |
21.2; 5.3 | — |
| SECONDARY Change in Time Above 10.0 mmol/L (180 mg/dL) |
-20.2; -7.9 | — |
| SECONDARY Change in Time Above 13.9 mmol/L (250 mg/dL) |
-8.9; -4.0 | — |
| SECONDARY Change in Mean Glucose Level |
-30.3; -8.2 | — |
| SECONDARY Change in Continuous Glucose Monitoring Coefficient of Variation (%) |
0.22; 0.06 | — |
| SECONDARY Change in Time Below 3.9 mmol/L (70 mg/dL) |
-0.11; -0.43 | — |
| SECONDARY Change in Time Below 3.0 mmol/L (54 mg/dL) |
-0.04; -0.17 | — |
| SECONDARY Basal Insulin Dose Changes |
1.23; 1.31 | — |
| SECONDARY Percent Acceptance Rate |
92.8 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 years or older at signing of informed consent
- Diagnosis of Type 2 Diabetes minimum 180 days before the day of screening
- Hemoglobin A1c between 7-9% and measured by local lab at screening
- On daily basal insulin for at least 90 days before inclusion into the study
- Stable dose of oral and injectable (other than insulin) antidiabetic medications for 90 days prior inclusion. Acceptable medications include:
- Metformin
- Sulfonylureas
- Meglitinides (glinides)
- Dipeptidyl peptidase 4 (DPP-4) inhibitors
- Sodium glucose co-transporter 2 (SGLT2) inhibitors
- Thiazolidinediones
- Alpha-glucosidase inhibitors
- Oral combination products (for the allowed individual oral anti-diabetic drugs)
- Oral or injectable Glucagon-like peptide-1 (GLP-1) Receptor Agonists (RAs)
- If on sulfonylureas or glinides, willingness to reduce dose by 50%
Exclusion Criteria
- Hypersensitivity to Degludec
- Use of an insulin pump
- Use of a short-acting insulin
- Participation or has participated in another trial within 90 days of the screening visit
- Female who is pregnant or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method
- Any disorder, except for conditions associated with T2D, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days of the screening visit
- Known skin reactions to CGM adhesives
- Current/prior use of CGM within 30 days of the screening visit
- Any planned surgery or procedures where basal insulin would be decreased or held in anticipation
Data sourced from ClinicalTrials.gov (NCT06111508). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.